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ABSTRACT
Introduction: Cytomegalovirus retinitis is one of the ocular manifestations of AIDS. 
The objective of the present study was to determine possible associations of class 
I and II HLA antigens and alleles in patients with AIDS and cytomegalovirus retinitis 
(CMV-R) with and without macular involvement.
Method: The study population consisted of 22 patients with AIDS and CMV-R with macular 
involvement (Group I), 19 patients with AIDS and CMV-R without macular involvement 
(Group II), and 202 individuals with negative serology for human immunodeficiency 
virus (Group III - control). Class I HLA antigens were typed by classical serology. Class 
II alleles were identified using sequence-specific oligonucleotide primers hybridized 
with amplified DNA.
Results: HLA-DRB1*14 and HLA-DRB1*10 specificities were more frequent among 
patients with macular involvement, possibly indicating greater susceptibility to this 
condition. In contrast, the HLA-B35 antigen may be associated with protection against 
macular involvement since it was significantly more frequent among patients without 
this involvement.
Conclusions: The HLA-DRB1*14 and HLA-DRB1*10 alleles may favor the development 
of CMV-R with macular involvement, whereas the HLA-B35 subtype may be associated 
with protection against macular involvement.
Keywords: HLA antigens; AIDS-related opportunistic infections; retinal diseases; 
cytomegalovirus retinitis
Cytomegalovirus (CMV) infections are important within the context of 
immunosuppression caused by human immunodeficiency virus (HIV-1), with 
CMV retinitis (CMV-R) representing a severe ocular infection in patients with 
AIDS, occurring more frequently when the CD4
+ lymphocyte count is below 
50 cells/mm3 1.
There is evidence that the human leukocyte antigen (HLA) system may 
be associated with patient susceptibility to/protection against CMV-R. Thus 
the HLA-B44 and HLA-DR7 subtypes2 and HLA-B513 may be associated 
with susceptibility to CMV-R, and the HLA-B8 antigen may be associated 
with protection4.
The observation of CMV-R cases with and without macular involvement 
may raise questions about the possibility that HLA subtypes also influence 
the localization of the lesions.
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Thus, the objective of the present study was to 
determine possible associations between antigens 
and class I and II HLA alleles and macular involvement 
in patients with AIDS and CMV-R.
METHODS
The present observational study was approved 
by the Research Ethics Committee of the University 
Hospital, Faculty of Medicine of Ribeirão Preto, 
University of São Paulo (Protocol nº 25.000-0490) 
and all patients gave written informed consent to 
participate.
The reference population for the initial detection of 
patients with CMV-R consisted of patients with AIDS 
followed up at the Unit for the Treatment of Infectious 
Diseases of the University Hospital, Faculty of Medicine 
of Ribeirão Preto (HCFMRP-USP), recruited from 
three sectors, i.e., outpatient clinic, day hospital, and 
ward. Patients referred for ophthalmological care to 
the Ophthalmology Sector of HCFMRP-USP were 
later added to the sample.
Forty-one patients (29 men) ranging in age from 
23 to 59 years (median: 33 years) participated in 
the study. Thirty were Caucasoids and 11 were 
Afro-descendants, according to the classification 
made by the Registry Sector of HCFMRP-USP.
HIV infection was diagnosed on the basis of the 
detection of serum antibodies by an immunoenzymatic 
method (Abbott Recombinant HIV-1/HIV-2 - IEA, 
Chicago, IL, USA). Positive results obtained by 
this method were confirmed by the gelatin particle 
agglutination test (Serodia, Fujirebio Inc., Tokyo, 
Japan).
Regardless of the group to which he/she belonged, 
each patient with AIDS diagnosed according to current 
criteria5 was subjected to ophthalmologic examination 
with emphasis on indirect binocular ophthalmoscopy 
and had blood samples collected for HLA typing.
The remaining data, including viral load and 
CD4
+ cell count, were obtained from the medical 
records of the patients.
Group I – Patients with AIDS and CMV-R with 
Macular Involvement
This group consisted of 22 adult patients with 
AIDS and CMV-R diagnosed by clinical and laboratory 
criteria who were studied regardless of whether or not 
they had started highly active antiretroviral treatment 
(HAART). They were required to present CMV 
involvement of the macular region of at least one eye, 
with consequent low visual acuity (VA <0.9 logMAR).
Group II – Patients with AIDS and CMV-R with-
out Macular Involvement
This group consisted of 19 adult patients with 
AIDS and CMV-R without macular involvement, as 
determined by ophthalmoscopy (example in figure 1), 
included in the study according to the same criteria 
used for Group I patients.
Group III – Controls
This group consisted of 202 adult individuals with 
negative HIV-1 serology from the same geographic 
area and with a similar genetic HLA profile as 
Group I and II patients. All subjects had negative 
serology for HIV (organ donors who were healthy 
until the date of donation) and their DNA is part of 
the Sample Bank of the Nucleus of Immunogenetic 
Research (BANPI), approved by the Research Ethics 
Committee of HCFMRP-USP (Protocol nº 7581/2007).
Ophthalmologic Exam
The ophthalmologic exam of Group I and II patients 
consisted of the measurement of VA and of indirect 
binocular ophthalmoscopy followed by retinography.
Snellen optotypes were used to assess VA, with 
the notations being transformed into logarithmic 
values – logMar6.
Fundoscopy was performed with an Omega 
100 indirect ophthalmoscope (Heine, Herrsching, 
Germany) with a 20-diopter lens (Nikon, Torrance, CA, 
USA) under mydriasis obtained with 1% tropicamide 
(Mydriacyl, Alcon, São Paulo, SP, Brazil). Retinographies 
were performed using a TRC-50X retinograph 
(Topcon, Tokyo, Japan).
For this study, we considered the anatomical 
macula, a circular area measuring 5 to 6 mm in 
diameter located between the superior and inferior 
temporal vascular arcades and reaching nasally the 
temporal margin of the optic disk (figure 2).
Figure 1: Retinography of patient with CMV-R macular 
involvement (Patient 2, Group II, right eye).
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Class I HLA Typing
Peripheral blood lymphocytes were obtained with 
heparin and separated on a Ficoll-Hypaque density 
gradient (1.077 g/mL).
HLA typing was performed by the complement 
dependent microlymphotoxicity reaction7 using the 
following HLA antisera: HLA-A (A1, A2, A3, A9, A10, 
A11, A19, A23, A24, A25, A26, A28, A29, A30, A31, 
A32, A33, A34, A36, A68, A69); HLA-B (B5, B7, B8, 
B12, B13, B14, B15, B16, B17, B18, B21, B22, B27, 
B35, B37, B38, B39, B40, B41, B42, B44, B45, B47, 
B48, B49, B50, B51, B52, B53, B54, B55, B57, B58, 
B60, B62, B63, B70).
Class II HLA Allele Typing (HLA-DRB1, HLA-
DRB3, HLA-DRB4, HLA-DRB5 and HLA-DQB1)
DNA was extracted by the salting-out technique8 and 
the polymerase chain reaction (PCR) was carried 
out using sequence-specific primers (SSP, Opels, 
Heildelberg, Germany)9. Class II HLA alleles were 
amplified using a Perkin Elmer 9600 thermocycler 
(Durham, NC, USA) under the following conditions: 
35 cycles at 94°C for 30 seconds, at 55 °C for 
1 minute, with an extension at 72 °C for 1 minute. 
The PCR products were separated by 2% agarose 
gel electrophoresis (Sigma) in Tris-borate and 
1% ethidium bromide.
Statistical Analysis
The frequency of class I HLA antigens and class 
II HLA alleles was compared between patients and 
controls using the two-tailed Fisher test.
RESULTS
Table 1 shows the VA levels in Group I and Group 
II participants. Clinical and demographic characteristics 
of Group I and Group II patients are shown in Table 2. Figure 2: Retinography of the eye fundus and macular area.
Table 1: Visual acuity (VA) of Group I and II patients.
GROUP I GROUP II
Patient no. VA-RE VA-LE Patient no. VA-RE VA-LE
1 LP LP 1 1 0.2
2 FC at 0.15 m FC at 2 m 2 0.7 0.0
3 0.5 LP 3 0.1 0.3
4 0.3 FC at 10 cm 4 0.0 0.0
5 0.7 FC at 10 cm 5 0.1 0.2
6 LP LP 6 0.1 0.1
7 LP LP 7 0.2 0.0
8 LP LP 8 0.3 1
9 FCt 1 m 0.3 9 0.8 0.0
10 0.0 FC at 3m 10 1 0.7
11 FC at 1 m FC at 1.5m 11 1 0.0
12 0.1 NIHIL 12 0.1 0.0
13 LP 0.1 13 0.0 0.3
14 NIHIL 0.4 14 0.1 0.3
15 FC at 2 m 0.7 15 0.4 0.7
16 0.0 LP 16 0.1 0.7
17 0.3 LP 17 0.1 0.0
18 0.0 LP 18 0.1 0.2
19 LP FC at 1m 19 0.0 0.0
20 0.0 NIHIL
21 0.0 LP
22 0.0 NIHIL
RE = right eye; LE = left eye; LP = light perception; FC = finger counting; NIHIL = absence of light perception.
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The frequency of Caucasoid participants was lower 
in group II than in group I, although the difference 
was not statistically significant.
The logarithms of the viral loads of Group I patients 
ranged from 3.96 to 6.44 (median=4.52) and of Group 
II participants from 3.95 to 6.92 (median=4.76), 
without differences.
The frequencies of HLA specificities that revealed 
statistically significant difference between groups are 
reported in Table 3 as absolute numbers (N) and 
relative numbers (%).
The only antigen that differed significantly 
between the groups with CMV-R was HLA-B35. For 
this reason, the patients carrying this antigen were 
evaluated and no statistically significant differences 
were observed between the two groups regarding 
variables such as number of opportunistic infections 
(p=0.5), CD4
+ lymphocyte count/mm3 (p=0.7) or viral 
load (p=0.2).
DISCUSSION
Despite the great advances in AIDS treatment, 
reducing the frequency of CMV-R, and the medications 
available for its treatment, this ocular complication 
is still a cause of reduced quality of life in patients 
with AIDS.
Compared to the control group, the subtypes 
HLA-B37, -B48, -B50, -DRB1*14, -DRB1*09, -DRB1*10, 
and -DQB1*04 were more frequent in Group I and 
the subtypes HLA-A26, -A34, -A36, -B35, -B42, 
-B45, and -DQB1*04 were more frequent in Group II.
However, the only specificities that differed 
significantly between groups were HLA-DRB1*14 and 
HLA-DRB1*10, indicating that the presence of these 
alleles favors the development of CMV-R with macular 
involvement (Group I x Group III), and HLA-B35, 
indicating that the presence of this antigen favors the 
development of CMV chorioretinitis without macular 
involvement (Group II x Group III). In addition, this 
last antigen was more frequent among Group II than 
Group I patients, suggesting that it protects against 
macular involvement.
It is known that the HLA-B35 antigen is one of the 
genes associated with the severity of AIDS and with 
the presence of T.gondii and CMV retinochoroiditis10-14 , 
and that a CD4
+ lymphocyte count of less than 
50 cells/mm3 is the main factor predisposing to the 
development of CMV-R, with the risk of these patients 
Table 2: Clinical and demographic characteristics of Group I and Group II patients.
Group I Group II
Patient
number
Age
(years) Gender
Ethnic 
Group
Number 
of 
infections
CD4+ 
cells/
mm3
Patient
number
Age
(years) Gender
Ethnic 
Group
Number 
of 
infections
CD4+ 
cells/
mm3
1 35 F C 3 7 1 32 M A 2 72
2 44 M C 4 45 2 35 M A 2 108
3 32 M C 7 7 3 27 F A 5 24
4 23 F A 4 157 4 40 M C 4 22
5 40 M C 4 103 5 34 M A 3 42
6 34 M C 6 76 6 37 M C 3 28
7 32 M C 2 2 7 36 M C 4 7
8 26 F C 4 110 8 32 M C 5 6
9 36 M A 5 72 9 35 M C 6 40
10 52 M C 3 42 10 33 F C 4 11
11 31 F C 3 90 11 24 M C 4 13
12 32 M A 5 47 12 32 M C 4 5
13 41 M C 3 23 13 32 M C 1 106
14 59 M C 2 25 14 34 M A 3 13
15 29 F C 5 11 15 30 F A 4 8
16 34 M C 6 98 16 33 F C 6 4
17 36 M C 4 210 17 29 M C 4 281
18 32 F C 2 33 18 26 F A 3 66
19 40 M C 4 30 19 33 M C 6 32
20 32 M C 1 3
21 39 F C 3 1
22 33 M A 4 34
M= male; F= female; C= Caucasoid; A= Afro-descendant.
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being 32.2 times higher than the risk of patients with 
CD4+ lymphocyte counts of 51-100/mm3 14,15.
Since all patients with CMV-R studied here had 
severe AIDS, the frequency of the HLA-B35 antigen 
was expected to be significantly higher in Groups 
I and II than in the general population. However, 
among the participants in this study, the frequency 
for Group I did not differ from that observed in the 
general population and was significantly lower 
compared to Group II.
Looking for a possible explanation, we analyzed 
the risk factors for the development of CMV-R at 
the time of diagnosis (number of opportunistic 
infections, CD4
+ cell count, and viral load) in Group 
I and II patients who presented the HLA-B35 antigen 
and observed that there were no significant differences 
between groups, although some Group I patients 
had higher counts than some of Group II patients.
As can also be seen in Table 3, the frequency of 
the HLA-DQB1*06 allele was lower in patients with 
macular involvement than in controls, indicating a 
protection against the development of CMV-R.
The only difference that would justify future 
investigation is the lower frequency of Caucasoids 
in the group without macular involvement. However, 
we did not find any literature report showing that 
African or Afro-descendant patients have lower 
macular involvement. Conversely, it was reported 
that genetic markers for hematologic diseases 
differed, in the northwest region of São Paulo State, 
according to race16.
The main limitation of the present study was 
the small sample size, although the participants 
represented about 90% of HCFMRP-USP patients with 
CMV-R seen during the total study period, since we 
only excluded patients whose conditions would have 
prevented the execution of the necessary exams, or 
who did not accept to participate in the study.
Thus, we did not detect HLA subtypes that might 
be considered to be markers of macular involvement 
or to protect against this involvement. However, the 
present results suggest that the HLA system may 
influence the development of the retinal lesions 
caused by CMV.
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Table 3: Absolute (N) and relative (%) numbers of HLA specificities that differed significantly between the groups of 
patients with AIDS and CMV-R (Group I – n = 22; 44 specificities – with macular involvement; Group II – n = 19; 38 
specificities – without macular involvement) and between these groups and the population control (Group III – n = 202; 
404 specificities).
Antigen
Group P Value
I
N(%)
II
 N(%)
III
N(%) I x II I x III II x III
HLA-B35 4(9.1) 11(28.9)   41(10.2) 0.02 Ns 0.02
HLA-DRB1*14(6+)  5(11.4) 1(2.6) 13(3.2) ns 0.023 ns
HLA-DRB1*10 3(6.8) 0   5(1.2) ns 0.034 ns
HLA-DQB1*06 3(6.8)   4(10.5)   96(23.8) ns 0.017 ns
ns= not significant.
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